Biodelivery Sciences International (BDSI) 14.92 $BDSI
BioDelivery Sciences Has Returned 12.0% Since SmarTrend Recommendation (BDSI)
Comtex SmarTrend(R) - Mon Feb 09, 10:00AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 3 months, BioDelivery Sciences has returned 12.00% as of today's recent price of $12.80.
BDSI: 14.92 (+0.93)
BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:07PM CST
BioDelivery (BDSI) entered into an agreement with Meda to obtain marketing authorizations for Onsolis.
BDSI: 14.92 (+0.93), OPHT: 51.11 (+0.12), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Podcast: Why the biotech boom is still in the 1st inning
ESTMZ - Wed Jan 28, 12:55PM CST
In the latest episode of our weekly podcast, This Week on Estimize , our CEO Leigh Drogen is joined by Joe McCann, a buy-side biotech analyst and the Founder of Slingshot Insights . Joe tells us why he believes the biotech boom still has plenty...
BDSI: 14.92 (+0.93), GILD: 101.90 (+1.10), RTRX: 13.92 (+0.44), ASPX: 65.76 (+2.76)
BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda
PR Newswire - Tue Jan 27, 6:00AM CST
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that it has entered into an assignment and revenue sharing agreement with Meda AB (Meda) under which Meda will transfer the marketing authorizations for ONSOLIS® (fentanyl buccal soluble film, CII) for the United States and the right to seek marketing authorizations for ONSOLIS in Canada and Mexico, back to BDSI. BDSI originally licensed such rights to Meda in 2007, and ONSOLIS was approved by the U.S. Food and Drug Administration (FDA) and originally commercially launched in the United States in 2009.
BDSI: 14.92 (+0.93)
Shares of BDSI Down 18.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 22, 9:58AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 2 months, BioDelivery Sciences has returned 18.53% as of today's recent price of $11.85.
BDSI: 14.92 (+0.93)
BioDelivery Sciences International (BDSI) in Focus: Stock Up 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 7:44AM CST
BioDelivery Sciences International, Inc. (BDSI) was a big mover last session, as the company saw its shares gain 5%
BDSI: 14.92 (+0.93), ALXN: 182.29 (+6.02)
BioDelivery Sciences Shares Down 16.8% Since SmarTrend's Sell Call (BDSI)
Comtex SmarTrend(R) - Thu Jan 15, 9:46AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 2 months, BioDelivery Sciences has returned 16.81% as of today's recent price of $12.10.
BDSI: 14.92 (+0.93)
15.8% Return Seen to Date on SmarTrend BioDelivery Sciences Call (BDSI)
Comtex SmarTrend(R) - Wed Jan 07, 11:11AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 2 months, BioDelivery Sciences has returned 15.78% as of today's recent price of $12.25.
BDSI: 14.92 (+0.93)
InsiderInsights.com Daily Round Up 12/30/14: XOMA, ECR, SNCR, AVK
InsiderInsights - at Seeking Alpha - Wed Dec 31, 10:49AM CST
BDSI: 14.92 (+0.93), ECR: 7.29 (+0.12), KFRC: 23.24 (+0.26), EVDY: 13.80 (-0.32), SAM: 303.26 (-0.97), AERI: 27.91 (+0.14), FUND: 7.47 (+0.05), RFMD: 16.59 (-0.35), AVK: 17.07 (-0.01), SNCR: 43.89 (+1.06), FTEK: 3.31 (+0.01), CAS: 6.14 (-0.01), COB: 10.25 (+0.18), XOMA: 3.41 (-0.01), CRM: 62.85 (+1.59)
Downtrend Call Working As BioDelivery Sciences Stock Falls 14.1% (BDSI)
Comtex SmarTrend(R) - Wed Dec 31, 10:00AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 1 month, BioDelivery Sciences has returned 14.13% as of today's recent price of $12.49.
BDSI: 14.92 (+0.93)
BioDelivery Is A Promising Biotechnology Bet
Value Insight - at Seeking Alpha - Tue Dec 30, 7:29AM CST
BDSI: 14.92 (+0.93), ENDP: 84.01 (+1.12)
Commit To Purchase BioDelivery Sciences International At $10, Earn 24.4% Annualized Using Options
at The Street - Mon Dec 29, 10:35AM CST
Investors considering a purchase of BioDelivery Sciences International Inc stock, but cautious about paying the going market price of $11.86/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
BDSI: 14.92 (+0.93)
Company News for December 26, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 9:10AM CST
Companies in the News are: CALM,ANFI,ADMS,BDSI
BDSI: 14.92 (+0.93), CALM: 35.73 (-0.42), ADMS: 16.98 (+0.03), ANFI: 8.84 (-0.42)
Endo and BioDelivery Sciences submit NDA for transmucosal pain med
Seeking Alpha - at Seeking Alpha - Thu Dec 25, 11:41AM CST
MNK: 115.01 (+2.51), BDSI: 14.92 (+0.93), ENDP: 84.01 (+1.12), EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)
Endo/BioDelivery File Regulatory Application for Pain Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:45PM CST
Endo International along with its partner BioDelivery Sciences International, Inc. announced the submission of a new drug application for buprenorphine HCl buccal film.
BDSI: 14.92 (+0.93), ENDP: 84.01 (+1.12), AUXL: 36.47 (-0.06), AMGN: 153.48 (+0.30)
Strong On High Volume: BioDelivery Sciences International (BDSI)
at The Street - Wed Dec 24, 9:01AM CST
Trade-Ideas LLC identified BioDelivery Sciences International (BDSI) as a strong on high relative volume candidate
BDSI: 14.92 (+0.93)
Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain
PR Newswire Europe - Tue Dec 23, 3:15PM CST
Endo Pharmaceuticals Inc., a subsidiary of Endo International plc , and BioDelivery Sciences International, Inc. announced today that they have submitted a New Drug Application (NDA) for Buprenorphine HCl Buccal Film to the U.S. Food and Drug Administration (FDA). Buprenorphine HCl Buccal Film is under development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
BDSI: 14.92 (+0.93), ENDP: 84.01 (+1.12), ENL.TO: 103.00 (unch)
BioDelivery Sciences Has Returned 12.0% Since SmarTrend Recommendation (BDSI)
Comtex SmarTrend(R) - Mon Feb 09, 10:00AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 3 months, BioDelivery Sciences has returned 12.00% as of today's recent price of $12.80.
BDSI: 14.92 (+0.93)
BioDelivery Signs Agreement with Meda for Onsolis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 3:07PM CST
BioDelivery (BDSI) entered into an agreement with Meda to obtain marketing authorizations for Onsolis.
BDSI: 14.92 (+0.93), OPHT: 51.11 (+0.12), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Podcast: Why the biotech boom is still in the 1st inning
ESTMZ - Wed Jan 28, 12:55PM CST
In the latest episode of our weekly podcast, This Week on Estimize , our CEO Leigh Drogen is joined by Joe McCann, a buy-side biotech analyst and the Founder of Slingshot Insights . Joe tells us why he believes the biotech boom still has plenty...
BDSI: 14.92 (+0.93), GILD: 101.90 (+1.10), RTRX: 13.92 (+0.44), ASPX: 65.76 (+2.76)
BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda
PR Newswire - Tue Jan 27, 6:00AM CST
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that it has entered into an assignment and revenue sharing agreement with Meda AB (Meda) under which Meda will transfer the marketing authorizations for ONSOLIS® (fentanyl buccal soluble film, CII) for the United States and the right to seek marketing authorizations for ONSOLIS in Canada and Mexico, back to BDSI. BDSI originally licensed such rights to Meda in 2007, and ONSOLIS was approved by the U.S. Food and Drug Administration (FDA) and originally commercially launched in the United States in 2009.
BDSI: 14.92 (+0.93)
Shares of BDSI Down 18.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 22, 9:58AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 2 months, BioDelivery Sciences has returned 18.53% as of today's recent price of $11.85.
BDSI: 14.92 (+0.93)
BioDelivery Sciences International (BDSI) in Focus: Stock Up 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 7:44AM CST
BioDelivery Sciences International, Inc. (BDSI) was a big mover last session, as the company saw its shares gain 5%
BDSI: 14.92 (+0.93), ALXN: 182.29 (+6.02)
BioDelivery Sciences Shares Down 16.8% Since SmarTrend's Sell Call (BDSI)
Comtex SmarTrend(R) - Thu Jan 15, 9:46AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 2 months, BioDelivery Sciences has returned 16.81% as of today's recent price of $12.10.
BDSI: 14.92 (+0.93)
15.8% Return Seen to Date on SmarTrend BioDelivery Sciences Call (BDSI)
Comtex SmarTrend(R) - Wed Jan 07, 11:11AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 2 months, BioDelivery Sciences has returned 15.78% as of today's recent price of $12.25.
BDSI: 14.92 (+0.93)
InsiderInsights.com Daily Round Up 12/30/14: XOMA, ECR, SNCR, AVK
InsiderInsights - at Seeking Alpha - Wed Dec 31, 10:49AM CST
BDSI: 14.92 (+0.93), ECR: 7.29 (+0.12), KFRC: 23.24 (+0.26), EVDY: 13.80 (-0.32), SAM: 303.26 (-0.97), AERI: 27.91 (+0.14), FUND: 7.47 (+0.05), RFMD: 16.59 (-0.35), AVK: 17.07 (-0.01), SNCR: 43.89 (+1.06), FTEK: 3.31 (+0.01), CAS: 6.14 (-0.01), COB: 10.25 (+0.18), XOMA: 3.41 (-0.01), CRM: 62.85 (+1.59)
Downtrend Call Working As BioDelivery Sciences Stock Falls 14.1% (BDSI)
Comtex SmarTrend(R) - Wed Dec 31, 10:00AM CST
SmarTrend identified a Downtrend for BioDelivery Sciences (NASDAQ:BDSI) on November 20th, 2014 at $14.55. In approximately 1 month, BioDelivery Sciences has returned 14.13% as of today's recent price of $12.49.
BDSI: 14.92 (+0.93)
BioDelivery Is A Promising Biotechnology Bet
Value Insight - at Seeking Alpha - Tue Dec 30, 7:29AM CST
BDSI: 14.92 (+0.93), ENDP: 84.01 (+1.12)
Commit To Purchase BioDelivery Sciences International At $10, Earn 24.4% Annualized Using Options
at The Street - Mon Dec 29, 10:35AM CST
Investors considering a purchase of BioDelivery Sciences International Inc stock, but cautious about paying the going market price of $11.86/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
BDSI: 14.92 (+0.93)
Company News for December 26, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 9:10AM CST
Companies in the News are: CALM,ANFI,ADMS,BDSI
BDSI: 14.92 (+0.93), CALM: 35.73 (-0.42), ADMS: 16.98 (+0.03), ANFI: 8.84 (-0.42)
Endo and BioDelivery Sciences submit NDA for transmucosal pain med
Seeking Alpha - at Seeking Alpha - Thu Dec 25, 11:41AM CST
MNK: 115.01 (+2.51), BDSI: 14.92 (+0.93), ENDP: 84.01 (+1.12), EGLT: 10.60 (+0.58), ZGNX: 1.43 (+0.05), PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), ALKS: 71.40 (-1.89), ACUR: 0.55 (+0.01)
Endo/BioDelivery File Regulatory Application for Pain Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:45PM CST
Endo International along with its partner BioDelivery Sciences International, Inc. announced the submission of a new drug application for buprenorphine HCl buccal film.
BDSI: 14.92 (+0.93), ENDP: 84.01 (+1.12), AUXL: 36.47 (-0.06), AMGN: 153.48 (+0.30)
Strong On High Volume: BioDelivery Sciences International (BDSI)
at The Street - Wed Dec 24, 9:01AM CST
Trade-Ideas LLC identified BioDelivery Sciences International (BDSI) as a strong on high relative volume candidate
BDSI: 14.92 (+0.93)
Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain
PR Newswire Europe - Tue Dec 23, 3:15PM CST
Endo Pharmaceuticals Inc., a subsidiary of Endo International plc , and BioDelivery Sciences International, Inc. announced today that they have submitted a New Drug Application (NDA) for Buprenorphine HCl Buccal Film to the U.S. Food and Drug Administration (FDA). Buprenorphine HCl Buccal Film is under development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
BDSI: 14.92 (+0.93), ENDP: 84.01 (+1.12), ENL.TO: 103.00 (unch)
